Alkermes Plc
NASDAQ:ALKS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.13
36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
ALKS
stock under the Base Case scenario is
27.195
USD.
Compared to the current market price of 31.405 USD,
Alkermes Plc
is
Overvalued by 13%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Alkermes Plc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Alkermes Plc
Balance Sheet Decomposition
Alkermes Plc
| Current Assets | 1.7B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 355m |
| Other Current Assets | 275.9m |
| Non-Current Assets | 588m |
| Long-Term Investments | 28m |
| PP&E | 326m |
| Intangibles | 84m |
| Other Non-Current Assets | 150m |
| Current Liabilities | 474m |
| Accounts Payable | 68m |
| Accrued Liabilities | 406m |
| Non-Current Liabilities | 122m |
| Other Non-Current Liabilities | 122m |
Free Cash Flow Analysis
Alkermes Plc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Alkermes Plc
|
Revenue
|
1.5B
USD
|
|
Cost of Revenue
|
-214m
USD
|
|
Gross Profit
|
1.3B
USD
|
|
Operating Expenses
|
-948.4m
USD
|
|
Operating Income
|
359m
USD
|
|
Other Expenses
|
-20m
USD
|
|
Net Income
|
339m
USD
|
ALKS Profitability Score
Profitability Due Diligence
Alkermes Plc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Alkermes Plc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
ALKS Solvency Score
Solvency Due Diligence
Alkermes Plc's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Score
Alkermes Plc's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALKS Price Targets Summary
Alkermes Plc
According to Wall Street analysts, the average 1-year price target for
ALKS
is 44.608 USD
with a low forecast of 30.3 USD and a high forecast of 58.8 USD.
Dividends
Current shareholder yield for
ALKS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ALKS
stock under the Base Case scenario is
27.195
USD.
Compared to the current market price of 31.405 USD,
Alkermes Plc
is
Overvalued by 13%.